Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin ablates force development during platelet mediated clot retraction

M E Carr1, S L Carr, P E Greilich

  • 1Department of Medicine, Medical College of Virginia, Richmond 23298-0230, USA.

Thrombosis and Haemostasis
|April 1, 1996
PubMed
Summary

Heparin significantly reduces platelet force development during cardiopulmonary bypass by interfering with thrombin activity. Protamine sulfate effectively reverses this inhibition, restoring platelet function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.

Haemophilia : the official journal of the World Federation of Hemophilia·2011
Same author

Re: Discordant pair analysis of rFVIIa and pd-aPCC response.

Haemophilia : the official journal of the World Federation of Hemophilia·2011
Same author

Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.

Haemophilia : the official journal of the World Federation of Hemophilia·2007
Same author

Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2007
Same author

Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease.

Journal of thrombosis and haemostasis : JTH·2006
Same author

Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.

Journal of thrombosis and haemostasis : JTH·2004

Area of Science:

  • Biochemistry
  • Hematology
  • Cardiovascular Surgery

Background:

  • Platelet function is crucial for hemostasis.
  • Cardiopulmonary bypass (CPB) impairs platelet function, leading to complications.
  • Heparin is commonly used during CPB but its effect on platelet force is not fully understood.

Purpose of the Study:

  • To investigate the role of heparin in reducing platelet force development during CPB.
  • To determine if heparin's effect is mediated by thrombin inhibition.

Main Methods:

  • Assessed platelet force development using a batroxobin-calcium system in citrated blood.
  • Studied the effects of varying heparin concentrations on platelet force and fibrin structure.
  • Investigated the impact of protamine sulfate on heparinized plasma.

Related Experiment Videos

  • Measured the effects of hirudin, a thrombin inhibitor, on platelet force.

    • Main Results:

    • Heparin at concentrations above 0.10 U/ml completely suppressed platelet force development.
    • Protamine sulfate restored platelet force development in heparinized plasma.
    • Heparin reduced fibrin fiber size by 33% at 1 U/ml.
    • Hirudin also inhibited platelet force development in a concentration-dependent manner.

    Conclusions:

    • Heparin significantly reduces platelet force development during CPB.
    • This reduction may be partly due to heparin's suppression of thrombin activity.
    • Understanding heparin's impact is vital for optimizing CPB procedures and patient outcomes.